Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q/A
Source: 0001731122-25-000250
Chunk: 9

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q/A
Chunk 9
---
 |   |     | $    |           — |   |
| SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES                   |     |                           |               |   |     |      |             |   |
| Finance agreement entered into in exchange for prepaid assets               |     | $                         |       906,834 |   |     | $    |   1,139,875 |   |
| Shares in lieu of interest on $1.2 million notes payable extension          |     | $                         |             — |   |     | $    |     204,392 |   |
| Common shares issued for contingent earn out liability                      |     | $                         |             — |   |     | $    |   2,762,500 |   |
| Conversion of note payable for issuance of preferred stock                  |     | $                         |     2,000,001 |   |     | $    |           — |   |
| Common shares issued upon acquisition                                       |     | $                         |   136,001,631 |   |     | $    |           — |   |
| Contingent consideration issued upon acquisition                            |     | $                         |    20,557,500 |   |     | $    |           — |   |
| Earn out shares issued in settlement of contingent liability                |     | $                         |     7,775,656 |   |     |      |           — |   |
| Note payable settled through non-cash exercise of warrants                  |     | $                         |     2,000,000 |   |     | $    |           — |   |
| Debt discount related to notes payable                                      |     | $                         |       301,841 |   |     | $    |           — |   |

<div align='center'>See accompanying notes to the unaudited condensed consolidated
financial statements.

7

RENOVARO INC. AND SUBSIDIARIES

NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Business– On February 13, 2024, the Company changed its corporate name from Renovaro Biosciences Inc. to Renovaro Inc.
(“Renovaro”, and together with its subsidiaries, the “Company”, “we” or “us”). In
August 202